» Articles » PMID: 28446656

Effect of a Long-term Intensive Lifestyle Intervention on Prevalence of Cognitive Impairment

Abstract

Objective: To assess whether an average of 10 years of lifestyle intervention designed to reduce weight and increase physical activity lowers the prevalence of cognitive impairment among adults at increased risk due to type 2 diabetes and obesity or overweight.

Methods: Central adjudication of mild cognitive impairment and probable dementia was based on standardized cognitive test battery scores administered to 3,802 individuals who had been randomly assigned, with equal probability, to either the lifestyle intervention or the diabetes support and education control. When scores fell below a prespecified threshold, functional information was obtained through proxy interview.

Results: Compared with control, the intensive lifestyle intervention induced and maintained marked differences in weight loss and self-reported physical activity throughout follow-up. At an average (range) of 11.4 (9.5-13.5) years after enrollment, when participants' mean age was 69.6 (54.9-87.2) years, the prevalence of mild cognitive impairment and probable dementia was 6.4% and 1.8%, respectively, in the intervention group, compared with 6.6% and 1.8%, respectively, in the control group ( = 0.93). The lack of an intervention effect on the prevalence of cognitive impairment was consistent among individuals grouped by cardiovascular disease history, diabetes duration, sex, and ε4 allele status (all ≥ 0.50). However, there was evidence ( = 0.03) that the intervention effect ranged from benefit to harm across participants ordered from lowest to highest baseline BMI.

Conclusions: Ten years of behavioral weight loss intervention did not result in an overall difference in the prevalence of cognitive impairment among overweight or obese adults with type 2 diabetes.

Clinicaltrialsgov Identifier: NCT00017953 (Action for Health in Diabetes).

Level Of Evidence: This study provides Class II evidence that for overweight adults with type 2 diabetes, a lifestyle intervention designed to reduce weight and increase physical activity does not lower the risk of cognitive impairment.

Citing Articles

Alzheimer Disease Blood Biomarkers and Cognition Among Individuals With Diabetes and Overweight or Obesity.

Mielke M, Evans J, Neiberg R, Molina-Henry D, Marcovina S, Johnson K JAMA Netw Open. 2025; 8(2):e2458149.

PMID: 39913137 PMC: 11803481. DOI: 10.1001/jamanetworkopen.2024.58149.


The Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT) intervention: A personalized approach to dementia risk reduction.

Barnes D, Balderson B, Shulman L, Rosenberg D, Matson T, Mettert K J Alzheimers Dis. 2024; 102(4):1121-1132.

PMID: 39623940 PMC: 11875122. DOI: 10.1177/13872877241296161.


Relationship between sex, APOE genotype, endocannabinoids and cognitive change in older adults with metabolic syndrome during a 3-year Mediterranean diet intervention.

Soldevila-Domenech N, Fagundo B, Cuenca-Royo A, Forcano L, Gomis-Gonzalez M, Boronat A Nutr J. 2024; 23(1):61.

PMID: 38862960 PMC: 11167771. DOI: 10.1186/s12937-024-00966-w.


Associations of an individual's need for cognition with structural brain damage and cognitive functioning/impairment: cross-sectional population-based study.

Truin L, Kohler S, Heger I, van Boxtel M, Schram M, Backes W Br J Psychiatry. 2023; 224(6):189-197.

PMID: 38105553 PMC: 7615981. DOI: 10.1192/bjp.2023.159.


The Role of Iron Overload in Diabetic Cognitive Impairment: A Review.

An J, Wang Q, Sun G, Su J, Liu J, Zhang C Diabetes Metab Syndr Obes. 2023; 16:3235-3247.

PMID: 37872972 PMC: 10590583. DOI: 10.2147/DMSO.S432858.


References
1.
Rovio S, Kareholt I, Helkala E, Viitanen M, Winblad B, Tuomilehto J . Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005; 4(11):705-11. DOI: 10.1016/S1474-4422(05)70198-8. View

2.
Ryan D, Espeland M, Foster G, Haffner S, Hubbard V, Johnson K . Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003; 24(5):610-28. DOI: 10.1016/s0197-2456(03)00064-3. View

3.
Joris P, Zeegers M, Mensink R . Weight loss improves fasting flow-mediated vasodilation in adults: a meta-analysis of intervention studies. Atherosclerosis. 2015; 239(1):21-30. DOI: 10.1016/j.atherosclerosis.2014.12.056. View

4.
Elosua R, Demissie S, Cupples L, Meigs J, Wilson P, Schaefer E . Obesity modulates the association among APOE genotype, insulin, and glucose in men. Obes Res. 2003; 11(12):1502-8. DOI: 10.1038/oby.2003.201. View

5.
Irie F, Fitzpatrick A, Lopez O, Kuller L, Peila R, Newman A . Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol. 2008; 65(1):89-93. PMC: 11070951. DOI: 10.1001/archneurol.2007.29. View